We use cookies

Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.

You can change your choice at any time.

MMedXYNews
HomeVideos
© 2026 MedXY
Contact usAbout usPrivacy PolicyMedXY story
MedXY AI/MedXY News/Psychiatry

Psychiatry

Ask MedXY AI
What is the latest evidence?Key clinical updatesGuideline changes

Latest news

Longitudinal Risk for Suicidal Self-Directed Violence Among Veterans With Cancer
newscancermental health

Longitudinal Risk for Suicidal Self-Directed Violence Among Veterans With Cancer

By MedXY|May 31, 2026

A national study of veterans with cancer found elevated suicide-related risk that persisted for years, especially among younger, unmarried, frail, or mentally ill patients and those with certain cancers such as central nervous system and th

Polygenic Scores Often Rival Recurrent CNVs for Psychiatric Risk Stratification, but Both Add Clinical Insight
newsPolygenic Scorespsychiatric genetics

Polygenic Scores Often Rival Recurrent CNVs for Psychiatric Risk Stratification, but Both Add Clinical Insight

By MedXY|May 31, 2026

A large Danish genetic study suggests recurrent CNVs and polygenic scores provide complementary psychiatric risk information, with polygenic scores often identifying more at-risk individuals and potentially modifying CNV-associated risk.

Integrating Rare and Common Variants: The Synergistic Role of rCNVs and Polygenic Scores in Psychiatric Risk Stratification
Clinical Updatescopy number variantsGenetic Psychiatry

Integrating Rare and Common Variants: The Synergistic Role of rCNVs and Polygenic Scores in Psychiatric Risk Stratification

By MedXY|May 31, 2026

This review synthesizes evidence on how recurrent copy number variants (rCNVs) and polygenic scores (PGSs) jointly influence psychiatric risk, highlighting their complementary roles in clinical risk assessment and the emergence of precision

When Severe Mental Illness Meets Lung Cancer: Why Equal Treatment Still Isn’t Guaranteed
newscancer disparitieslung cancer

When Severe Mental Illness Meets Lung Cancer: Why Equal Treatment Still Isn’t Guaranteed

By MedXY|May 29, 2026

A large Japanese study found that people with schizophrenia spectrum disorders were less likely to receive several standard treatments for non-small cell lung cancer, underscoring a persistent and preventable gap in cancer care.

Patients With Schizophrenia Spectrum Disorder Are Less Likely to Receive Stage-Appropriate Treatment for Non-Small Cell Lung Cancer in Japan
newsJapanNon-Small Cell Lung Cancer

Patients With Schizophrenia Spectrum Disorder Are Less Likely to Receive Stage-Appropriate Treatment for Non-Small Cell Lung Cancer in Japan

By MedXY|May 29, 2026

A nationwide Japanese cohort study found that patients with schizophrenia spectrum disorder and NSCLC presented with more advanced disease and were less likely to receive surgery, adjuvant chemotherapy, or systemic therapy.

Association Between Delivery Mode and Postpartum Psychiatric Conditions
newspsychiatryvaginal delivery

Association Between Delivery Mode and Postpartum Psychiatric Conditions

By MedXY|Aug 18, 2026

A large U.S. cohort study found higher rates of postpartum psychiatric conditions after planned or unplanned cesarean delivery, but not after successful operative vaginal delivery, highlighting the need for closer postpartum mental health f

Semaglutide Improves Insulin Sensitivity in Patients With Schizophrenia, Prediabetes, and Obesity Treated With Second-Generation Antipsychotics: Findings From the HISTORI Trial
Diabetes & Endocrinologyantipsychoticsinsulin sensitivity

Semaglutide Improves Insulin Sensitivity in Patients With Schizophrenia, Prediabetes, and Obesity Treated With Second-Generation Antipsychotics: Findings From the HISTORI Trial

By MedXY|May 26, 2026

In a 30-week randomized trial, semaglutide improved insulin sensitivity, reduced insulin resistance, lowered fasting glucose, and produced substantial weight loss in patients with schizophrenia and prediabetes taking second-generation antip

Health Plan Disenrollment and Mortality After Starting Medications for Opioid Use Disorder
newsbuprenorphinehealth insurance

Health Plan Disenrollment and Mortality After Starting Medications for Opioid Use Disorder

By MedXY|May 23, 2026

A large cohort study found that health plan disenrollment after starting buprenorphine or naltrexone for opioid use disorder was linked to higher all-cause and overdose mortality, highlighting the importance of continuous coverage and treat

Efficacy and Safety of Psilocybin in Treatment-Resistant Major Depression: The EPISODE Randomized Clinical Trial
newspsilocybinpsychiatry

Efficacy and Safety of Psilocybin in Treatment-Resistant Major Depression: The EPISODE Randomized Clinical Trial

By MedXY|May 18, 2026

Psilocybin-assisted psychotherapy showed promising but inconclusive antidepressant effects in treatment-resistant depression, with notable acute adverse events and safety concerns.

Implementation of a Hospital-Based Screening and Treatment Program for Unhealthy Alcohol Use
newsAlcohol Use Disorderbrief intervention

Implementation of a Hospital-Based Screening and Treatment Program for Unhealthy Alcohol Use

By MedXY|May 18, 2026

A hospital-based screening and treatment program for unhealthy alcohol use was feasible in a diverse safety-net population and was linked to short-term reductions in alcohol risk scores, especially among patients who received follow-up and

Patient-Derived Neuronal Synapse Deficits Predict Brain Network Abnormalities and Cognitive Impairment in Schizophrenia
NeurologycognitioniPSC

Patient-Derived Neuronal Synapse Deficits Predict Brain Network Abnormalities and Cognitive Impairment in Schizophrenia

By MedXY|May 15, 2026

A multimodal translational study links genetically driven synaptic deficits in patient-derived neurons to cortical structure, electrophysiology, and cognition in schizophrenia, supporting biologically informed stratification of cognitive im

Extended-Release vs Sublingual Buprenorphine in Pregnancy Through 12 Months Post Partum: A Randomized Clinical Trial
OB/GYN & Women's Healthmaternal healthPregnancy

Extended-Release vs Sublingual Buprenorphine in Pregnancy Through 12 Months Post Partum: A Randomized Clinical Trial

By MedXY|Aug 18, 2026

A clinical trial found that weekly extended-release buprenorphine significantly improves illicit opioid abstinence during pregnancy compared to sublingual forms, with fewer serious adverse events, offering a safer treatment option for opioi

Initiation of Medications for Alcohol Use Disorder Among Hospitalized Veterans : A Retrospective Cohort Study
Internal MedicineAlcohol Use DisorderVeterans Health

Initiation of Medications for Alcohol Use Disorder Among Hospitalized Veterans : A Retrospective Cohort Study

By MedXY|May 11, 2026

VHA study reveals only 30% of veterans hospitalized for AUD receive evidence-based medications during or shortly after hospitalization, with significant variation across hospitals and demographic factors influencing prescription rates.

A CBT-Based Mobile App Significantly Reduced Tinnitus Distress in a Sham-Controlled Randomized Trial
newsCognitive Behavioral Therapydigital therapeutic

A CBT-Based Mobile App Significantly Reduced Tinnitus Distress in a Sham-Controlled Randomized Trial

By MedXY|May 11, 2026

In a 60-patient randomized trial, a digital therapeutic app delivering tinnitus education and CBT elements produced large, durable reductions in tinnitus-related distress over 16 weeks, with no serious safety concerns.

Intersection of Intimate Partner Violence and Substance Use Disorders in the Veteran Population: Screening Gaps, Risk Profiles, and Lethality
Clinical UpdatesIntimate Partner ViolenceSubstance Use Disorders

Intersection of Intimate Partner Violence and Substance Use Disorders in the Veteran Population: Screening Gaps, Risk Profiles, and Lethality

By MedXY|May 12, 2026

This review synthesizes evidence on the high prevalence and severity of intimate partner violence (IPV) among veterans with substance use disorders, highlighting gender-specific lethality risks and the critical need for integrated screening

Semaglutide Reduced Effort Discounting and Improved Motivation Signals in Major Depressive Disorder
Diabetes & EndocrinologyGLP-1 receptor agonistmajor depressive disorder

Semaglutide Reduced Effort Discounting and Improved Motivation Signals in Major Depressive Disorder

By MedXY|May 5, 2026

In a 16-week randomized trial, adjunctive oral semaglutide improved effort-based decision-making in adults with major depressive disorder and overweight or obesity, suggesting a potential role for GLP-1 receptor agonism in reward-related dy

SAIA-MH Strategy Boosts Mental Health Outcomes in Mozambique: A Breakthrough in Low-Resource Settings
newscare cascadeKhoa học Triển khai

SAIA-MH Strategy Boosts Mental Health Outcomes in Mozambique: A Breakthrough in Low-Resource Settings

By MedXY|Apr 21, 2026

The Systems Analysis and Improvement Approach for Mental Health (SAIA-MH) significantly improved functional outcomes, medication adherence, and appointment attendance in Mozambican outpatient clinics, offering a scalable model for low-resou

Digital Mental Health Interventions Show Promise for Black and Female Health Care Workers
newsEquityhealth care workers

Digital Mental Health Interventions Show Promise for Black and Female Health Care Workers

By MedXY|Apr 21, 2026

A proactive digital mental health platform improved mental health outcomes for health care workers, with notable benefits for Black and female participants in work productivity and sustained depression reduction.

Semaglutide Shows Promise in Reducing Mental Illness Worsening in Patients with Depression and Anxiety, Swedish Study Finds
Diabetes & Endocrinologyanxietydepression

Semaglutide Shows Promise in Reducing Mental Illness Worsening in Patients with Depression and Anxiety, Swedish Study Finds

By MedXY|Apr 13, 2026

A landmark Swedish cohort study of 95,490 patients reveals that semaglutide is associated with a 42% lower risk of worsening mental illness in people with depression and anxiety, while other GLP-1 receptor agonists show varied effects. The

Machine Learning Falls Short in Personalizing School-Based Mindfulness for Adolescent Depression Prevention: MYRIAD Trial Insights
newsAdolescent Depressionmachine learning

Machine Learning Falls Short in Personalizing School-Based Mindfulness for Adolescent Depression Prevention: MYRIAD Trial Insights

By MedXY|Apr 13, 2026

Secondary analysis of the MYRIAD trial reveals that while machine learning models can identify adolescents who may benefit from school-based mindfulness training, the clinical relevance of such predictions remains minimal. Both causal fores

Prev
5 / 20
1…34567…20
Next
Ask MedXY AI

Most popular

Intimate Health
Five Benefits for Women Continuing Sexual Activity After Menopause
Intimate Health
Why Some Women Have a Strong Sex Drive—And Why Men Shouldn't Worry About It
Nursing & care
How often should a couple have sex?
General Surgery
Optimizing Postoperative Opioid Prescriptions After Intra-Abdominal Cancer Surgery: Comparing the 5x-Multiplier and 3-Tier Models
Intimate Health
Classic Intimacy Recommendations: How to Help Women Reach Orgasm and Enjoy Mutual Pleasure

Browse by specialty

Open language-specific specialty feeds and department pages.

news6829 articlesCardiology1403 articlesClinical Updates1315 articlesOncology1176 articlesDiabetes & Endocrinology868 articlesNeurology834 articlesPublic Health605 articlesGastroenterology586 articles
Hematology-Oncology
513 articles
Pediatrics493 articles
Internal Medicine464 articles